BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38888469)

  • 21. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
    Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
    PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma.
    de Oliveira S; Houseright RA; Korte BG; Huttenlocher A
    Dis Model Mech; 2020 Apr; 13(4):. PubMed ID: 32102783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
    Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
    Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
    Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME
    Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Use of Fluorescence
    Weiel JJ; Forgo B; Sage J; Rangaswami A; Hazard FK
    Ann Clin Lab Sci; 2022 May; 52(3):475-483. PubMed ID: 35777788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma.
    Dinh TA; Vitucci EC; Wauthier E; Graham RP; Pitman WA; Oikawa T; Chen M; Silva GO; Greene KG; Torbenson MS; Reid LM; Sethupathy P
    Sci Rep; 2017 Mar; 7():44653. PubMed ID: 28304380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
    Abou-Alfa GK; Mayer R; Venook AP; O'Neill AF; Beg MS; LaQuaglia M; Kingham PT; Kobos R; Basturk O; Brennan C; Yopp A; Harding JJ; Leong S; Crown J; Hoti E; Leonard G; Ly M; Bradley M; Valentino E; Markowitz D; Zukiwski A; Ren K; Gordan JD
    Oncologist; 2020 Dec; 25(12):e1837-e1845. PubMed ID: 32154962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
    Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
    Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
    Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.
    RĂ¼land L; Andreatta F; Massalini S; Chuva de Sousa Lopes S; Clevers H; Hendriks D; Artegiani B
    Nat Commun; 2023 May; 14(1):2377. PubMed ID: 37137901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
    Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
    Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non coding RNA analysis in fibrolamellar hepatocellular carcinoma.
    Farber BA; Lalazar G; Simon EP; Hammond WJ; Requena D; Bhanot UK; La Quaglia MP; Simon SM
    Oncotarget; 2018 Feb; 9(12):10211-10227. PubMed ID: 29535801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
    Kim J; Kim Y; Lee B
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.
    Riggle KM; Turnham R; Scott JD; Yeung RS; Riehle KJ
    Pediatr Blood Cancer; 2016 Jul; 63(7):1163-7. PubMed ID: 26990031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformational Landscape of the PRKACA-DNAJB1 Chimeric Kinase, the Driver for Fibrolamellar Hepatocellular Carcinoma.
    Tomasini MD; Wang Y; Karamafrooz A; Li G; Beuming T; Gao J; Taylor SS; Veglia G; Simon SM
    Sci Rep; 2018 Jan; 8(1):720. PubMed ID: 29335433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A framework for fibrolamellar carcinoma research and clinical trials.
    Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
    Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins.
    Averill AM; Rehman HT; Charles JW; Dinh TA; Danyal K; Verschraegen CF; Stein GS; Dostmann WR; Ramsey JE
    J Cell Biochem; 2019 Aug; 120(8):13783-13791. PubMed ID: 30938854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene Rearrangement and Expression of PRKACA and PRKACB Govern Morphobiology of Pancreatobiliary Oncocytic Neoplasms.
    Itoh T; Omori Y; Seino M; Hirose K; Date F; Ono Y; Mizukami Y; Aoki S; Ishida M; Mizuma M; Morikawa T; Higuchi R; Honda G; Okamura Y; Kinoshita K; Unno M; Furukawa T
    Mod Pathol; 2024 Jan; 37(1):100358. PubMed ID: 37871652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.
    Abdelhamed W; El-Kassas M
    World J Gastrointest Oncol; 2022 Jun; 14(6):1103-1114. PubMed ID: 35949219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
    Lalazar G; Simon SM
    Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.